Hot Investor Mandate 3: Pharma Firm Looks for Innovative Technologies in CNS, Kidney Disorders and Oncology

19 Oct

A global pharmaceutical company with offices in Japan and the USA focuses on developing and marketing products in the pharmaceutical and nutraceutical businesses. Currently, the firm is actively seeking in-licensing opportunities to strengthen their product portfolio, and will consider all global opportunities.

The firm is interested in innovative therapeutics that address areas of significant unmet need in the following indications: CNS, nephrology, and oncology, in descending order. CNS is the area in which the firm has the strongest interest and expertise, and the firm is opportunistic to all types of sub-indications that fall under CNS, including Alzheimer’s disease, schizophrenia, etc. In nephrology, the firm is particularly interested in therapeutics in chronic kidney disease (CKD) and complications that are linked to CKD (i.e. hyponatremia), as well as IgA nephropathy and acute kidney injury. In oncology, the firm is primarily interested in therapeutics being developed for hematological cancers. The firm will consider assets as early as pre-clinical, but such assets will ideally be IND-ready with a valid proof-of-concept.

The firm has no specific management team requirements and will work with all types of companies with an innovative product or pipeline. The firm does not always seek distribution rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: